comparemela.com

Latest Breaking News On - Arcturus therapeutics holdings - Page 11 : comparemela.com

Are Arcturus Therapeutics Holdings Inc s (NASDAQ:ARCT) Fundamentals Good Enough to Warrant Buying Given The Stock s Recent Weakness?

With its stock down 37% over the past three months, it is easy to disregard Arcturus Therapeutics Holdings.

Arcturus therapeutics holdingsArcturus therapeutics holdings using its retained earningsTherapeutics holdingsArcturus therapeuticsArnings growth

Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government

$165 million in manufacturing grants awarded to ARCALIS by the Japanese government .

United statesSan diegoSeika pharmaJoseph payneMrna technologyJapanese ministry of economyArcturus therapeutics holdings incArcturus therapeutics holdingsJapanese ministryChief executive officerMeiji seika pharmaPrivate securities litigation reform actAnnual report

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) Shares Sold by Byrne Asset Management LLC

Byrne Asset Management LLC decreased its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 16.7% during the 2nd quarter, Holdings Channel reports. The firm owned 3,500 shares of the biotechnology company’s stock after selling 700 shares during the quarter. Byrne Asset Management LLC’s holdings in Arcturus Therapeutics were worth $100,000 at the […]

William blairKeithc kummerfeldByrne asset managementDaiwa securities group incArcturus therapeutics company profileWells fargo companySecurities exchange commissionGreen alpha advisorsHoldings channelCharles schwab investment management incGreat west life assurance coArcturus therapeutics holdings incArcturus therapeutics holdingsFree reportAsset managementArcturus therapeutics

Byrne Asset Management LLC Lowers Stock Holdings in Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT)

Byrne Asset Management LLC trimmed its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 16.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 3,500 shares of the biotechnology company’s stock after selling 700 shares during the period. Byrne Asset Management LLC’s holdings […]

Keithc kummerfeldWilliam blairDimensional fund advisorsHermes incArcturus therapeutics holdings incWells fargo companyCharles schwab investment management incVanguard group incMetlife investment managementCantor fitzgeraldByrne asset managementSecurities exchange commissionArcturus therapeutics holdingsFree reportAsset managementArcturus therapeutics

Arcturus Therapeutics (ARCT) and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032

Arcturus Therapeutics (ARCT) and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Cystic fibrosis foundation cfCf foundationCystic fibrosis foundationArcturus therapeutics holdings incArcturus therapeutics holdingsPad chivukulaChief scientific officer

vimarsana © 2020. All Rights Reserved.